Retatrutide appears to be a new treatment in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By activating these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately contributes to significant slimming. While